VYXEOS LIPOSOMAL 44mg/100mg 44mg+100mg powder for concentrate infusion solution medication leaflet

L01XY01 • daunorubicin + cytarabine • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Combinations of antineoplastic agents

The combination of Daunorubicinum + Cytarabinum is used for the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed patients. It combines the chemotherapeutic effects of daunorubicin and cytarabine to destroy cancer cells and induce remission.

The medications are administered intravenously according to a specific regimen and are effective in reducing tumor burden and prolonging patient survival. This combination is considered standard in AML treatment.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, cardiac toxicity or other severe complications may occur. Close monitoring is essential.

Consult your doctor to discuss the benefits and risks of treatment with Daunorubicinum + Cytarabinum. Follow all medical recommendations to ensure treatment effectiveness.